Literature DB >> 20056540

Novel bis-arylsulfonamides and aryl sulfonimides as inactivators of plasminogen activator inhibitor-1 (PAI-1).

Nadine C El-Ayache1, Shih-Hon Li, Mark Warnock, Daniel A Lawrence, Cory D Emal.   

Abstract

Inactivators of plasminogen activator inhibitor-1 (PAI-1) have been identified as possible treatments for a range of conditions, including atherosclerosis, venous thrombosis, and obesity. We describe the synthesis and inhibitory activity of a novel series of compounds based on bis-arylsulfonamide and aryl sulfonimide motifs that show potent and specific activity towards PAI-1. Inhibitors containing short linking units between the sulfonyl moieties and a 3,4-dihydroxy aryl substitution pattern showed the most potent inhibitory activity, and retained high specificity for PAI-1 over the structurally-related serpin anti-thrombin III (ATIII). Copyright (c) 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20056540      PMCID: PMC2957478          DOI: 10.1016/j.bmcl.2009.12.051

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  28 in total

1.  Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis.

Authors:  G A McMahon; E Petitclerc; S Stefansson; E Smith; M K Wong; R J Westrick; D Ginsburg; P C Brooks; D A Lawrence
Journal:  J Biol Chem       Date:  2001-07-05       Impact factor: 5.157

2.  Characterization of a novel class of polyphenolic inhibitors of plasminogen activator inhibitor-1.

Authors:  Jacqueline M Cale; Shih-Hon Li; Mark Warnock; Enming J Su; Paul R North; Karen L Sanders; Maria M Puscau; Cory D Emal; Daniel A Lawrence
Journal:  J Biol Chem       Date:  2010-01-08       Impact factor: 5.157

3.  Effect of pharmacologic plasminogen activator inhibitor-1 inhibition on cell motility and tumor angiogenesis.

Authors:  C E Leik; E J Su; P Nambi; D L Crandall; D A Lawrence
Journal:  J Thromb Haemost       Date:  2006-10-02       Impact factor: 5.824

4.  Protection from high fat diet-induced increase in ceramide in mice lacking plasminogen activator inhibitor 1.

Authors:  Charmi Shah; Guang Yang; Ian Lee; Jacek Bielawski; Yusuf A Hannun; Fahumiya Samad
Journal:  J Biol Chem       Date:  2008-03-22       Impact factor: 5.157

Review 5.  PAI-1 - a potential therapeutic target in cancer.

Authors:  Peter A Andreasen
Journal:  Curr Drug Targets       Date:  2007-09       Impact factor: 3.465

6.  A PAI-1 mutant, PAI-1R, slows progression of diabetic nephropathy.

Authors:  Yufeng Huang; Wayne A Border; Ling Yu; Jiandong Zhang; Daniel A Lawrence; Nancy A Noble
Journal:  J Am Soc Nephrol       Date:  2008-01-23       Impact factor: 10.121

7.  S35225 is a direct inhibitor of Plasminogen Activator Inhibitor type-1 activity in the blood.

Authors:  Alain Rupin; Roger Gaertner; Philippe Mennecier; Isabelle Richard; Alain Benoist; Guillaume De Nanteuil; Tony J Verbeuren
Journal:  Thromb Res       Date:  2008-02-21       Impact factor: 3.944

8.  Synthesis and evaluation of N,N'-bis(arylsulfonyl)hydrazines as antineoplastic agents.

Authors:  K Shyam; L A Cosby; A C Sartorelli
Journal:  J Med Chem       Date:  1985-04       Impact factor: 7.446

9.  Dose-dependent thrombus resolution due to oral plaminogen activator inhibitor (PAI)-1 inhibition with tiplaxtinin in a rat stenosis model of venous thrombosis.

Authors:  Sanjiv Baxi; David L Crandall; Thomas R Meier; Shirley Wrobleski; Angela Hawley; Diana Farris; Hassan Elokdah; Robert Sigler; Robert G Schaub; Thomas Wakefield; Daniel Myers
Journal:  Thromb Haemost       Date:  2008-04       Impact factor: 5.249

10.  Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: design, synthesis, and preclinical characterization.

Authors:  Hassan Elokdah; Magid Abou-Gharbia; James K Hennan; Geraldine McFarlane; Cheryl P Mugford; Girija Krishnamurthy; David L Crandall
Journal:  J Med Chem       Date:  2004-07-01       Impact factor: 7.446

View more
  3 in total

1.  From bifunctional to trifunctional (tricomponent nucleophile-transition metal-lewis acid) catalysis: the catalytic, enantioselective α-fluorination of acid chlorides.

Authors:  Jeremy Erb; Daniel H Paull; Travis Dudding; Lee Belding; Thomas Lectka
Journal:  J Am Chem Soc       Date:  2011-04-22       Impact factor: 15.419

Review 2.  Effects of altered plasminogen activator inhibitor-1 expression on cardiovascular disease.

Authors:  Victoria A Ploplis
Journal:  Curr Drug Targets       Date:  2011-11       Impact factor: 3.465

Review 3.  Pharmaceutical and medicinal significance of sulfur (SVI)-Containing motifs for drug discovery: A critical review.

Authors:  Chuang Zhao; K P Rakesh; L Ravidar; Wan-Yin Fang; Hua-Li Qin
Journal:  Eur J Med Chem       Date:  2018-11-22       Impact factor: 6.514

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.